



BRCA/BRCAness targeting in cancer: from bench to bedside and back

Verona, Thursday September 19th, 2019
Aula B - Lente Didattica · Policlinico G. B. Rossi

Presentation

Genetic predisposition to cancer has recently taken center stage in the management of cancer patients and their families for several reasons: i) with more widespread testing, we have realized that the prevalence of hereditary genetic alterations is higher than expected; ii) universal testing for cancer-predisposing genes is being increasingly proposed in cancer patients; iii) hereditary cancer genes have become established biomarkers not just of cancer risk in healthy individuals, but also of sensitivity to specific drug treatments in cancer patients.

Universal BRCA1/2 testing, in particular, is considered mandatory in women affected by non-mucinous ovarian cancer and has been recently proposed in breast, prostate and pancreatic cancer. Such practice and increasing evidence of the therapeutic impact of platinum-based chemotherapy and PARP inhibitors are changing clinical practice and raising new questions:

1) Why don't all BRCA-mutant patients respond to therapy in the same way? 2) What are the biological mechanisms underlying treatment sensitivity/resistance in a BRCA-mutant context? 3) How can resistance be overcome in BRCA-mutant tumors? 4) How do we use information about BRCA mutations in the clinical setting? 5) How do we test for BRCA mutations? How do we define and identify BRCAness? How do we deal with the results of NGS panels testing for a wider spectrum of cancer-predisposing genes?

We have asked a panel of internationally recognized experts in the field of BRCA-related cancer biology and therapy to share their views, practices and original research to find answers to these questions and novel ideas in this extremely fertile and relevant field, which truly represents a translational challenge in a Precision Oncology era.

Michele Milella

Scientific program

9:15 - 9:45	Welcome Breakfast
9:30 - 9:45	Welcome and introduction <i>Michele Milella</i>
9:45 - 10:30	Clinical BRCAness and current therapeutic approaches to BRCA-defective tumors <i>Talia Golan, Tel Aviv, Israel</i>
10:30 - 11:15	BRCA1/2 aberrations and BRCAness: how should we detect them? <i>Aldo Scarpa, Verona, Italy</i>
11:15 - 11:45	Guidelines for testing: Scientific Societies' Recommendations <i>Raffaella Casolino, Verona, Italy</i>
11:45 - 12:15	Q&A

BRCA/BRCAness targeting in cancer: from bench to bedside and back

Verona, Thursday September 19th, 2019
Aula B - Lente Didattica · Policlinico G. B. Rossi

Speakers

Talia Golan

MD, PhD, Oncology Institute, Sheba Medical Center, Tel Hashomer, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Aldo Scarpa

Director of the Applied Research on Cancer – Network (ARC-Net) Research Centre of the University and Hospital Trust of Verona and Director of Dept. of Pathology University Hospital of Verona

Raffaella Casolino

MD, PhD Student, Oncology, University of Verona

Venue

**Aula B - Lente Didattica · Policlinico G. B. Rossi
Piazzale Scuro, 10 - 37134 Verona**

How to reach the meeting venue:

- Motorway exit: Verona Sud, then follow indications to Policlinico Borgo Roma
- From Verona Porta Nuova Railway Station, 4 km far from the meeting venue: taxi or bus n. 21, 22, 62, 70, 72 - Stop Piazzale Scuro.

How To Register

The registration is free and reserved up to **50 participants**. It is possible to register online by September 10, 2019 on the website www.cogest.info. Select the event from the section "Agenda congressi" and click on "Iscriviti online". Upon receipt of the registration, a confirmation message from the Organizing Secretariat will be sent. If you cannot attend anymore, please inform the Organizing Secretariat as soon as possible.

Scientific Secretariat

Prof. Michele Milella

Director of the Residency Program in Medical Oncology,
University of Verona - School of Medicine

Dott. Daniela Cafaro

UOC Oncologia
University of Verona - School of Medicine

Organizing Secretariat



COGEST M. & C. srl

Vicolo San Silvestro 6 · 37122 Verona (Italy)
Phone: 0039 045 597940 · Fax: 0039 045 597265
E-mail: cogest@cogest.info · www.cogest.info